Remote Opioid Monitoring Act of 2023

Bill: 118-hr-4093
Sponsor: full_name: Rep. Balderson, Troy [R-OH-12]
Introduced: 2023-06-14
Policy area: Health
Subjects: Congressional oversight

Government studies and investigations

Health information and medical records

Health technology, devices, supplies

Prescription drugs
Latest action: action_date: 2023-06-16
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2023-06-14
action_desc: Introduced in House
text: <p><strong>Remote Opioid Monitoring Act of 2023</strong></p><p>This bill requires the Government Accountability Office (GAO)&nbsp;to report on the use of remote monitoring of individuals who are prescribed opioids, including the efficacy and prevalence of remote monitoring with respect to these individuals. GAO must also recommend ways to improve the availability, access, and coverage of remote monitoring for these individuals.</p>

tv_txt: I 118th CONGRESS 1st Session H. R. 4093 IN THE HOUSE OF REPRESENTATIVES June 14, 2023 Mr. Balderson (for himself and Ms. Kelly of Illinois ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To provide for a study on the effects of remote monitoring on individuals who are prescribed opioids.

1. Short title This Act may be cited as the Remote Opioid Monitoring Act of 2023 . 2. Providing for a study on the effects of remote monitoring on individuals who are prescribed opioids (a) In general Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall conduct a study and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Committee on Finance of the Senate a report on the use of remote monitoring with respect to individuals who are prescribed opioids. (b) Report The report described in subsection (a) shall include— (1) an assessment of scientific evidence related to the efficacy, individual outcomes, and potential cost savings associated with remote monitoring for individuals who are prescribed opioids compared to such individuals who are not so monitored; (2) an assessment of the current prevalence of remote monitoring for individuals who are prescribed opioids, including the use of such monitoring for such individuals in other countries; and (3) recommendations to improve availability, access, and coverage for remote monitoring for individuals who are prescribed opioids, including through changes to Federal health care programs (as defined in section 1128B of the Social Security Act ( 42 U.S.C. 1320a–7b )) and, if determined appropriate by the Comptroller General, an identification of cohorts of individuals who stand to benefit the most from remote monitoring when prescribed opioids.